IL17A and COVID-19: We found, that the risk of COVID-19-related death over time was significantly increased in patients with more than 100 dead lymphocytes in 1 μl (P = 0.0026), less than 5% of early apoptotic lymphocytes (P = 0.0081), less than 85% of CD14+/HLA-Dr+ monocytes (P = 0.029), increased expression of JNK in PBMCs (>200 MFI, P = 0.034), increased serum levels of IL-17 (>7 pg/ml, P = 0.037) and decreased PAI-1 serum levels (< 40 pg/ml, P = 0.00073).